Literature DB >> 19005938

Design and evaluation of matrices of Eudragit with polycarbophil and carbopol for colon-specific delivery.

Laila Fatima Ali Asghar1, Sajeev Chandran.   

Abstract

The purpose of the present study was to investigate the effect of incorporating pH-responsive polymers Eudragit (L100 or S100) in matrix bases composed of hydrophilic polymers polycarbophil and carbopol to design oral controlled release formulations with sigmoidal release profile for colon-specific delivery. Matrix tablets were prepared by wet granulation technique using indomethacin as model drug and were characterized for physical parameters, in vitro drug release, release kinetics, and stability on storage. The gastrointestinal (GI) transit of selected formulations was also investigated in human subjects using gamma scintigraphy. In vitro release studies indicated that the presence of pH-sensitive polymers in hydrophilic polymer base retarded the initial release significantly (10-15% release in 6 h) followed with controlled release for the next 8-10 h in simulated GI fluid pH (without enzymes). The presence of Eudragit in hydrophilic matrix base retarded the swelling of the matrix base in acidic to weakly acidic pH, but in alkaline pH, enhancement in drug release rate was observed due to the dissolution of Eudragit from the base resulting in a porous matrix structure, resulting in around 80-90% release in 14 h of study. In vivo gamma scintigraphy studies in healthy human subjects proved that the formulations had acceptable matrix strength to withstand gastric and colonic transit. The mean colonic residence time of selected designed formulations varied between 15 and 19 h. Such a matrix design could have potential application as colon-specific drug delivery systems with pH- and time-dependent drug release profile.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19005938     DOI: 10.1080/10611860802473345

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  7 in total

1.  Once daily, high-dose mesalazine controlled-release tablet for colonic delivery: optimization of formulation variables using Box-Behnken design.

Authors:  Ahmed Abd Elbary; Ahmed A Aboelwafa; Ibrahim M Al Sharabi
Journal:  AAPS PharmSciTech       Date:  2011-10-29       Impact factor: 3.246

2.  Influence of some formulation variables on the optimization of pH-dependent, colon-targeted, sustained-release mesalamine microspheres.

Authors:  Ahmed Abd El-Bary; Ahmed A Aboelwafa; Ibrahim M Al Sharabi
Journal:  AAPS PharmSciTech       Date:  2011-12-01       Impact factor: 3.246

3.  Colon specific delivery of indomethacin: effect of incorporating pH sensitive polymers in xanthan gum matrix bases.

Authors:  Laila F A Asghar; Chetan B Chure; Sajeev Chandran
Journal:  AAPS PharmSciTech       Date:  2009-04-21       Impact factor: 3.246

4.  Design and evaluation of matrix base with sigmoidal release profile for colon-specific delivery using a combination of Eudragit and non-ionic cellulose ether polymers.

Authors:  Laila Fatima Ali Asghar; Sajeev Chandran
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

5.  Preparation of Colon-Targeted Acetylharpagide Tablets and its Release Properties in vivo and in vitro.

Authors:  DeWen Liu; Huijie Yan; Yiming Kong; Yun You; Yanling Li; Lixin Wang; Yan Tong; Jinyu Wang
Journal:  Front Pharmacol       Date:  2018-08-14       Impact factor: 5.810

6.  Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach.

Authors:  Ummarah Kanwal; Shahid Mukhtar; Muzzamil Waheed; Arifa Mehreen; Nasir Abbas; Rahat Shamim; Khalid Hussain; Fatima Rasool; Amjad Hussain; Nadeem Irfan Bukhari
Journal:  Drug Des Devel Ther       Date:  2021-05-24       Impact factor: 4.162

7.  Formulation and in vitro evaluation of Eudragit S-100 coated naproxen matrix tablets for colon-targeted drug delivery system.

Authors:  Rohit Mehta; Anuj Chawla; Pooja Sharma; Pravin Pawar
Journal:  J Adv Pharm Technol Res       Date:  2013-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.